We recently designed and engineered an oHSV, named R-613, completely detargeted from its natural receptors, and retargeted to EGFRvIII, a mutated form of the epidermal growth factor, typical of human glioblastoma [33]. The gene discussed is EGF; the disease is glioblastoma.